Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause
of blindness in the Western world. Currently, anti-vascular endothelial growth factor (VEGF)
intravitreal injections (IVI) remain the standard-of-care treatment for wAMD. Previous
studies show that about 90% of treated patients lose minimal visual function after 2 years of
follow-up. There is still, a subset of 15% patients, incomplete responders, that do not
improve and possibly worsen due to the persistence of sub-retinal fluid (with or without
intra-retinal fluid) with chronic treatment.
The investigators plan to evaluate the effect of oral doxycycline versus placebo on the
anatomic and functional outcomes in persistent sub-retinal eye fluid in neovascular wet
age-related macular degeneration. This subset are incomplete or non-responders to current
anti-VEGF intravitreal therapy.